WO2001032319A9 - Embout d'applicateur d'adhesif avec un dispositif d'amorçage de la polymerisation, modificateur de vitesse de polymerisation et/ou materiel bioactif - Google Patents

Embout d'applicateur d'adhesif avec un dispositif d'amorçage de la polymerisation, modificateur de vitesse de polymerisation et/ou materiel bioactif

Info

Publication number
WO2001032319A9
WO2001032319A9 PCT/US2000/041648 US0041648W WO0132319A9 WO 2001032319 A9 WO2001032319 A9 WO 2001032319A9 US 0041648 W US0041648 W US 0041648W WO 0132319 A9 WO0132319 A9 WO 0132319A9
Authority
WO
WIPO (PCT)
Prior art keywords
applicator
applicator tip
tip
polymerization
flavorant
Prior art date
Application number
PCT/US2000/041648
Other languages
English (en)
Other versions
WO2001032319A3 (fr
WO2001032319A2 (fr
Inventor
Upvan Narang
William S C Nicholson
Daniel L Hedgpeth
Gabriel N Szabo
Ibraheem T Badejo
Joe B Barefoot
William M Cotter
Alessio Keith R D
Anthony Sherbondy
Original Assignee
Closure Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Closure Medical Corp filed Critical Closure Medical Corp
Priority to AU36380/01A priority Critical patent/AU3638001A/en
Publication of WO2001032319A2 publication Critical patent/WO2001032319A2/fr
Publication of WO2001032319A3 publication Critical patent/WO2001032319A3/fr
Publication of WO2001032319A9 publication Critical patent/WO2001032319A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/442—Colorants, dyes

Definitions

  • This invention relates to applicators for applying biomedical adhesives and sealants, methods of making them, and methods of applying such adhesives and sealants. More particularly, this invention relates to methods of applying a bioactive agent, polymerization rate modifier, and/or polymerization initiator to an applicator tip; applicators and applicator tips produced by such methods; and methods of using the applicators in medical, surgical, and other topical applications.
  • Sutures are recognized to provide adequate wound support.
  • sutures cause additional trauma to the wound site (by reason of the need for the needle and suture to pass through tissue and the need to anesthetize the wound area via needle puncture) and are time-consuming to place, and, at skin level, can cause unattractive wound closure marks.
  • Surgical staples have been developed to speed wound apposition and provide improved cosmetic results.
  • surgical staples also impose additional wound trauma and require the use of ancillary and often expensive devices for positioning and applying the staples. Both sutures and staples are especially problematic in pediatric cases where the patient may have a strong fear response and refuse to cooperate with their placement, and in geriatric cases where the skin tissue is weaker and prone to tearing.
  • adhesives have been proposed for use in wound closure.
  • adhesives have been proposed for use in wound covering and protection in such topical applications as surface lacerations, abrasions, stomatitis, and other open surface wounds.
  • One group of such adhesives is the monomeric forms of ⁇ -cyanoacrylates.
  • the cyanoacrylate surgical adhesive is applied to one or both surfaces of a wound or incision, including the internal portions of the wound, with any excess adhesive being quickly removed from the bonding surfaces. Subsequently, the edges of the wound are held together until they adhere.
  • An additional method of application of the cyanoacrylate surgical adhesive to wounds or incisions involves the formation of a bridge over the wound site. As described in U.S. Patent No. 3,667,472 to Halpern, incised tissues are held together and maintained in fixed relationship until a cyanoacrylate adhesive has been applied over the incision and allowed the necessary time to develop a bond.
  • a method for application of a topical cyanoacrylate tissue adhesive is disclosed in product literature accompanying Histoacryl ® adhesive, which is commercially available from B. Braun Melsungen AG of Germany. The manufacturer recommends use of this adhesive only for closure of minor skin wounds and not for internal use. Moreover the manufacturer recommends that the adhesive be used sparingly or in thin films because thick films do not increase the film strength and can lead to necrosis of surrounding tissue due to thermogenic polymerization of the cyanoacrylate adhesive.
  • cyanoacrylate adhesives are applied in monomeric form to the surfaces to be joined, sealed, or otherwise treated.
  • in situ anionic polymerization of the monomer occurs, giving rise to the desired adhesive bond or covering.
  • moisture and/or proteins naturally present in the treated tissues initiate polymerization of the adhesives.
  • Histoacryl ® adhesive polymerization can proceed rapidly, with the generation of high levels of heat, which often damage the tissues at or near the site of application.
  • the tissue can first be dried, for example by sponging, to remove essentially all tissue fluids from the site. In this method, there is essentially no water to initiate polymerization. Therefore, polymerization proceeds relatively slowly, often taking greater than 150 seconds, for example. This system, while effective, does not provide a high level of convenience for the user due to the extended time often required for polymerization.
  • cyanoacrylate polymerization inhibitors or stabilizers including Lewis acids, such as sulfur dioxide, nitric oxide, boron trifluoride, and other acidic substances, including hydroquinone monomethyl ether, hydroquinone, nitrohydroquinone, catechol, and hydroquinone monoethyl ether have been used.
  • inhibitors are disclosed in, for example, U.S. Patent No. 3,559,652 to Banitt, the subject matter of which is incorporated herein by reference.
  • the addition of these inhibitors and stabilizers inhibits premature polymerization of the monomer and slows down the rate of polymerization once the composition is in contact with the tissue to be treated.
  • Mclntire et al. disclose a nozzle for use on containers for holding cyanoacrylate adhesives so that the cyanoacrylate compositions do not begin to polymerize on exposure to moisture in the air.
  • the nozzle comprises a moldable material having an organic acid dispersed therein that inhibits the polymerization of cyanoacrylates while in the nozzle.
  • the organic acids are incorporated into the moldable material prior to extrusion forming of the nozzle.
  • the caffeine or theobromine is added to the adhesive composition in one of two ways.
  • the caffeine or theobromine can be mixed with the cyanoacrylate adhesive composition by stirring just prior to application of the adhesive to the substrates to be joined.
  • the caffeine or theobromine is dissolved in a volatile solvent, applied to the surfaces to be joined, the volatile solvent is allowed to evaporate, and then the cyanoacrylate adhesive composition is applied to the surfaces of the substrates to be joined. Both of these methods, while effective, are inconvenient for the user because two separate solutions or two separate applications are required.
  • incorporation of the initiator or the rate modifier into the applicator tip provides convenience because only a single composition is required, and allows a level of control over the polymerization rate that cannot be achieved through reliance on polymerization initiators or rate modifiers naturally present at the wound site (such as water).
  • the polymerization initiators and/or rate modifiers are incorporated into the applicator tip by spraying, dipping, or brushing the applicator tip with a solvent (also referred to herein as a liquid medium) containing the initiator and/or rate modifier.
  • a solvent also referred to herein as a liquid medium
  • Low boiling point solvents such as acetone and ethanol, or mixtures thereof are used to apply the initiator and/or rate modifier.
  • the applicator tips disclosed in this commonly assigned patent effectively and conveniently permit mixing of a cyanoacrylate composition with a polymerization initiator or a polymerization rate modifier during dispensing.
  • the polymerization reaction that ensues can be highly exothermic, and, like other methods currently in use, can cause tissue damage at the site of application due to excessive heat generation during polymerization.
  • bioactive materials are medicaments which are added to the adhesive compositions to aid in the healing process when the cyanoacrylate adhesives are used to close wounds.
  • U.S. Patent No. 5,684,042 to Greff et al. discloses a cyanoacrylate composition comprising an antimicrobially-effective amount of an iodine-contaitiing antimicrobial agent.
  • the iodine-containing antimicrobial agent is dispersible in the cyanoacrylate composition and does not cause premature polymerization of the cyanoacrylate adhesive (i.e., does not initiate polymerization).
  • U.S. Patents Nos. 5,514,371 and 5,624,669 to Leung, et al. disclose the addition of a therapeutic agent in a cyanoacrylate composition.
  • the cyanoacrylate adhesive forms a matrix for the therapeutic agent, with the therapeutic agent being released in vivo over time from the matrix during biodegradation of the polymer.
  • U.S. Patent No. 4,940,579 to Randen discloses a composition comprising a medicament and a cyanoacrylate adhesive.
  • the composition is used to deliver medicaments to non-mucosal areas of mammal bodies.
  • U.S. Patent No. 5,254,132 to Barley et al. discloses the use of cyanoacrylate adhesives in conjunction with antibiotics.
  • the antibiotics are added to the cyanoacrylate compositions and stored in a sterile applicator for use in a single-dose application.
  • the composition is maintained in a sealed container to avoid polymerization prior to application; therefore, the antibiotic does not initiate or accelerate polymerization of the adhesive composition.
  • U.S. Patent No. 5,866,106 to Papay discloses the addition of vitamins and minerals in a cyanoacrylate composition.
  • the cyanoacrylate adhesive composition is disclosed as useful for an adhesive for bonding nail tips, and for forming a nail polish product.
  • the present invention provides a method of applying at least one material to an applicator tip used to dispense liquid compositions.
  • the material may be applied to the applicator tip using a solvent comprising methanol and further comprising another low boiling point solvent, such as a low molecular weight ketone or alcohol, or a mixture thereof.
  • a low molecular weight ketone or alcohol such as a low molecular weight ketone or alcohol, or a mixture thereof.
  • low molecular weight ketones and alcohols are those which have three or fewer carbon atoms in their main chain.
  • the solvent consists essentially or entirely of methanol.
  • the material is incorporated into the applicator tip during the manufacturing process of the applicator tip.
  • a desired distribution profile of the material on, and/or within, the applicator tip can be achieved without the need for an extra step of applying the material to an already formed applicator tip.
  • the material is applied to an applicator tip such that the material is present on the tip in a gradient or anisotropically (i.e., in a pattern that is not identical in all directions within the tip).
  • the material is present on the tip in a gradient, where there is a greater amount of the material at the distal end of the tip (the end where the liquid composition exits the applicator tip during dispensing) as compared to the proximal end (the end where the liquid composition enters the applicator tip during dispensing).
  • the material is an initiator and/or a rate modifier for polymerization and/or cross-linking of a polymerizable monomer.
  • a polymerization initiator is any material that causes a monomer composition applied to a substantially dry tissue (i.e., substantially in the absence of plasma or like tissue fluids) to polymerize in less than 300 seconds at ambient temperature, for example, at approximately 21-25°C.
  • the initiator causes the monomer composition to polymerize in less than 150 seconds at ambient temperature, more preferably within
  • a polymerization rate modifier is any material that changes the rate at which a polymerizable monomer would polymerize in the absence of that material.
  • the rate modifier accelerates the rate of the polymerization reaction.
  • the initiator or rate modifier is an accelerator or catalyst.
  • the initiator and/or rate modifier is bioactive.
  • the material applied to the tip is bioactive or a flavorant, but not an initiator or rate modifier for polymerization and/or cross-linking of the polymerizable monomer.
  • the present invention also provides a method of using an applicator tip containing a polymerization and/or cross-linking initiator, a polymerization and/or cross-linking rate modifier, and/or a bioactive material and/or a flavorant to apply a monomeric composition to a desired site, such as a wound, a surgical site, or any other topical or deep tissue site.
  • the method is used to treat wounds or to treat or protect topical sites, such as areas of skin prone to wounding.
  • the present invention also provides a method of delivering a bioactive material to a tissue.
  • tissue includes any tissue of a human or animal, such as skin, mucous membranes, oral/nasal tissues, gastrointestinal tissues, organ tissues, tumors, non-keratinous tissues, etc.
  • the present invention further provides an applicator tip that has a polymerization or cross-linking initiator, a polymerization and/or cross-linking rate modifier, and/or a bioactive material and/or a flavorant on or in it.
  • Applicator tips according to the present invention provide several advantages, including the ability to: a) control the molecular weight distribution of the polymerized or cross- linked adhesive; b) control the setting time of the polymerized or cross-linked adhesive; c) provide precision and convenience in applying the adhesive to a tissue; d) extend the shelf life of the monomer; e) reduce the amount of unreacted monomer at the completion of the polymerization reaction, thus avoiding associated monomer odors after polymerization; f) control the flow properties of applied cyanoacrylate adhesives; g) provide a bioactive material and/or flavorant to a wound site while simultaneously providing wound closure, protection, and/or coverage; and/or h) combinations thereof.
  • FIG. 1 depicts an applicator of the invention, showing the distribution of a polymerization rate modifier or a polymerization initiator in an applicator tip applied with methanol.
  • Fig. 2 shows a cross section of the applicator of Fig. 1 along the A- A line.
  • Fig. 3 depicts an applicator showing the distribution of a polymerization rate modifier or a polymerization initiator on an applicator tip applied with acetone.
  • Fig. 4 shows a cross section of the applicator of Fig. 3 along the A-A line.
  • Fig. 5 shows the polymerization temperatures of a 2-octyl cyanoacrylate composition dispensed through applicator tips having an initiator applied with methanol and with acetone.
  • Fig. 6 shows the relationship between setting time (time required for polymerization) of a 2-octyl cyanoacrylate composition and concentration of initiator. The figure also shows the time required for polymerization of a 2-octyl cyanoacrylate composition dispensed through tips having an initiator applied with methanol and with acetone.
  • the setting time, or the amount of time required for polymerization, of a 2-octyl cyanoacrylate composition is slightly longer when the cyanoacrylate composition is dispensed through a tip having a benzalkonium chloride initiator disposed thereon using methanol as compared to using acetone.
  • Figures 1-4 show effects of different solvents used to apply a polymerization initiator or a polymerization rate modifier to an applicator tip.
  • the initiator or rate modifier is applied to the tip by pumping a liquid medium comprising the initiator or rate modifier through a syringe and onto the distal end of the tip.
  • Figure 1 shows an applicator tip 2 of applicator 1 treated with a solution of an initiator or rate modifier dissolved in 110 ⁇ L of methanol, and subsequently dried for about 30 minutes.
  • Figure 2 shows a cross-section of the applicator and tip in Figure 1.
  • the initiator or rate modifier is present on the tip in a concentration gradient.
  • the initiator or rate modifier concentration is highest at the top, or distal, end of the applicator tip and decreases towards the center and bottom, or proximal, end of the applicator tip.
  • Figure 3 shows an applicator tip treated with a solution of an initiator or rate modifier dissolved in 110 ⁇ L of acetone, and subsequently dried for about 30 minutes.
  • Figure 4 shows a cross-section of the applicator and tip in Figure 3.
  • the initiator or rate modifier is present on the tip in a concentration gradient that increases from the top (distal) end towards the bottom (proximal) end of the applicator tip.
  • the pattern of distribution of the material within the tip when applied using a solvent comprising methanol, provides unexpectedly superior polymerization characteristics to monomer compositions dispensed through the tip as compared to compositions dispensed through tips prepared using other low boiling point solvents, such as acetone.
  • the monomer compositions dispensed through tips prepared using solvents comprising methanol polymerize rapidly enough to make them convenient to apply; however, the polymerization that occurs does not result in the level of tissue damage often seen when other systems of cyanoacrylate delivery are used.
  • the solvent (also referred to herein as the liquid medium) for application of the material comprises methanol.
  • Methanol can be used as the only solvent, or it can be present in mixtures of methanol with other low boiling point solvents, including low molecular weight ketones such as acetone.
  • the mixture can be in any ratio.
  • the mixture is a ratio of methanol to other solvent of between 99:1 to 1:99.
  • the ratio of methanol to other solvent can be approximately 80:20 to 20:80, or 60:40 to 40:60.
  • the solvent comprises a component other than methanol
  • the other component is a low boiling point solvent having a vapor pressure of about 25 - 150 mm Hg at 20°C, such as about 30-125 mm Hg at 20°C, or about 40-100 mm Hg at 20°C, or mixtures thereof.
  • low molecular weight solvents can be used. Included are low molecular weight ketones and alcohols.
  • a material may be applied to an applicator tip with other solvents, including water. The material may be applied to the applicator tip by spraying, dipping, injecting, or brushing the applicator tip with a liquid medium containing the material. It is preferably applied to the tip by dipping or injecting. For example, it may be applied to the tip by pumping of the liquid medium, for example, through a syringe, onto the distal end of the tip.
  • the material may be applied to the applicator tip by using a vacuum or pressure process.
  • a solution or suspension of the material is introduced into a vacuum or pressure chamber.
  • the applicator tips either individually or preferably in batches, are placed into the solution or suspension in the pressure vessel in a manner such that the applicator tips preferably do not float to the top of the solution or suspension.
  • the applicator tips can be placed in the solution or suspension in a wire basket or other suitable container, which would hold the applicator tips under the solution or suspension, or a wire mesh or other suitable retainer could be placed over the applicator tips to dunk or sink them into the solution or suspension.
  • the vessel can be sealed and an appropriate vacuum or pressure applied.
  • preparing an applicator for dispensing polymerizable monomeric compositions includes applying a material to a suitable applicator tip, such as a porous polyethylene tip or a foam or fibrous swab, which is attached to an applicator body, such as a butyrate applicator tube or an applicator handle such as a plastic, wood, metal or other suitable material handle or holder.
  • a suitable applicator tip such as a porous polyethylene tip or a foam or fibrous swab
  • an applicator body such as a butyrate applicator tube or an applicator handle such as a plastic, wood, metal or other suitable material handle or holder.
  • the applicator body or tube may comprises a conduit or reservoir for the polymerizable monomeric composition.
  • the applicator tip may be operably connected to the conduit or reservoir, such as by being fitted on an open end of the conduit, so that fluid flowing through the conduit also flows through the applicator tip.
  • the applicator body may be free of an adhesive reservoir and may be intended to function only as a handle by which to grip the applicator, without itself containing the polymerizable monomeric composition.
  • the applicator body can be a solid or hollow tube, such as a pipe, stick, rod, dowel, or the like, either straight or contoured.
  • Such embodiments can be, for example, intended to apply a polymerizable monomeric composition by dipping the applicator into the polymerizable monomeric composition or dripping the monomeric composition onto the tip, rather than forcing the polymerizable monomeric composition through the applicator tip from the applicator handle.
  • solvents comprising methanol also provides adequate bonding of the butyrate applicator tube or applicator body to a polyethylene applicator tip.
  • the solvent used to apply the material to the tip also helps bond the polyethylene applicator tip to the butyrate applicator tube or applicator body.
  • Solvents comprising methanol while still providing the bonding that is necessary to hold the tip to the tube or applicator, allow the use of a greater range of solvent amounts to apply the material to the tip.
  • An anisotropic distribution or a concentration gradient of material in the applicator tip can be obtained with the use of a methanol-containing solvent.
  • the distribution of the material may be varied depending on the solvent or solvents used to apply it and on the wetting characteristics of the solvent and tip.
  • the wetting characteristics of the solvent should be such that the surface tension is close enough to that of the tip material to wet at least the surface of the tip.
  • the material applied to the applicator tip can be any material, but is preferably an initiator that initiates polymerization and/or cross-linking of the monomer; a polymerization rate modifier, which modifies the rate of polymerization of the monomer; a bioactive material, such as a medicament; and/or a flavorant.
  • the material may be applied to a surface portion or to the entire surface of the applicator tip. Preferably, only a portion of the exterior of the applicator tip is treated with the material.
  • Particular initiators and rate modifiers for particular monomers may be readily selected by one of skill in the art without undue experimentation.
  • Suitable polymerization initiators and rate modifiers for cyanoacrylate compositions include, but are not limited to, detergent compositions; surfactants, including nonionic surfactants such as polysorbate 20 (e.g., Tween 20TM; ICI Americas), polysorbate 80 (e.g., Tween 80TM; ICI Americas), and poloxamers; cationic surfactants such as tetrabutylammonium bromide; anionic surfactants, including quaternary ammonium halides such as benzalkonium chloride or its pure components, and benzethonium chloride; stannous octoate (tin (II) 2-ethylhexanoate), and sodium tetradecyl sulfate; and amphoteric or zwitterionic surfactants such as dodecy
  • surfactants including nonionic surfactants such as polysorbate 20 (e.g., Tween 20TM; ICI Americas), polysorbate
  • the initiator may be a bioactive material, including quaternary ammonium halides such as alkylbenzyldimethylammonium chloride (benzalkonium chloride; BAG) its pure components, or mixtures thereof, especially those with an alkyl containing 6-18 carbon atoms; benzethonium chloride; and salts of sulfadiazine. Cobalt napthenate can be used as an accelerator for peroxide.
  • the initiator may be a bioactive material that possesses antiviral, antimicrobial, antifungal and/or wound healing properties.
  • Gentian Violet also known as crystal violet or methylrosaniline chloride.
  • materials that possess polymerization initiation and wound healing properties also include various zinc complexes and zinc salts, antioxidants such as vitamin E and other vitamins and the like, and copper compounds such as copper chloride, copper sulfate and copper peptides, as described in "Copper: An Essential Element for Life," ProCyte
  • Such materials are particularly preferred because they can serve not only as the polymerization initiator or rate modifier for the cyanoacrylate monomer, they can also provide additional benefits to the wound site, such as antiviral effects, antimicrobial effects and/or antifungal effects or help to promote wound healing.
  • the zinc compound can be present in various forms, such as zinc salts.
  • suitable zinc compounds include, but are not limited to, zinc salts of cyanoacrylic acid, zinc salts of cyanoacetic acid, zinc salts of dicyanoglutaric acid, zinc salts of rosin, zinc oxide, zinc salts of polycyanoacrylic acid, zinc salts of polyacrylic acid, zinc bacitracin, zinc salicylate, zinc stearate, zinc citrate, zinc lactate, mixtures thereof, and the like.
  • the zinc compounds are of Zn 2+ . Incorporation of such zinc compounds into the applied cyanoacrylate composition, either prior to or concurrent with application and/or initiation, is particularly effective in promoting wound healing of leg ulcers, thermal burns, and the like.
  • crystal violet is particularly preferred. Crystal violet has many benefits, particularly when used in conjunction with the adhesive monomer compositions of the present invention. One benefit of crystal violet is that in addition to providing the antiviral, antimicrobial and/or antifungal effects, it also provides a visible color at the site of application, which can help ensure that a sufficient or desired amount of adhesive has been applied. However, whereas crystal violet is known to leave "tattoo" scars on tissue when it is applied, such tattoo scarring does not result when it is used in combination with the adhesive monomer compositions of the present invention. Rather, the crystal violet provides its coloring and other effects, without leaving a long-term or permanent mark.
  • the crystal violet can be incorporated in the applicator tip in various amounts, to provide different results.
  • it can be incorporated in small amounts, such as that amount necessary to provide the desired amount of polymerization initiation, without leaving significant amounts in the polymerized compositions, and thus without providing significant or effective antiviral, antimicrobial and/or antifungal effect.
  • the crystal violet provides the composition with a visible color prior to and during the polymerization, but the color fades as the crystal violet is consumed in polymerization.
  • a larger amount of crystal violet can be incorporated into the applicator tip, such that an effective amount of the material remains even after polymerization to provide the desired antiviral, antimicrobial and/or antifungal effects.
  • the mode of application of the crystal violet to the applicator tip can be varied to obtain desired composition gradients of the material in the applicator tip. For example, if it is desired to maintain the crystal violet only one or near the surface of the applicator tip, then it can be applied, for example, with acetone as described above. Alternatively, if it is desired to incorporate the crystal violet more evenly throughout the applicator tip, then it can be applied, for example, with methanol as also described above. In embodiments, the crystal violet, and/or other agents being added to the applicator tip, can be applied using water as a solvent.
  • the polymerizable and/or cross-linkable material may also contain an initiator and/or a rate modifier which is inactive until activated by a catalyst or accelerator (included within the scope of the term "initiator” as used herein) in the applicator tip.
  • Initiators activated by stimulation such as heat and/or light (e.g., ultraviolet or visible light) are also suitable if the tip and/or applicator is appropriately subjected to such stimulation.
  • the initiator or rate modifier may be dissolved or otherwise dispersed in the solvent and applied to the applicator tip in any effective amount.
  • An effective amount is that amount of initiator or rate modifier that effects polymerization to a gel point on dry tissue in less than 300 seconds, preferably within 150 seconds, and more preferably within 130 seconds, at ambient temperature, such as approximately 21- 25°C.
  • the coated applicator is then allowed to dry, thereby evaporating the solvent. In embodiments, the applicator is allowed to dry for about 5 to 35 minutes.
  • the amount of initiator or modifier dissolved or dispersed in the solvent may be about, or less than, 25 wt.%, preferably less than 10 wt.% and more preferably less than 1 wt.%.
  • the amount of initiator or rate modifier dissolved or dispersed in the solvent may be any effective amount.
  • the effective amount is preferably between 100 and 250 ppm or more in 110 ⁇ l.
  • the effective amount is preferably approximately 50 ppm or more in 110 ⁇ l.
  • the effective amount for each initiator and adhesive monomer combination can easily be determined by one of ordinary skill in the art.
  • an appropriate volume of a solution of the initiator prepared in a volatile solvent is placed in a differential scanning calorimetric pan.
  • the volatile solvent is allowed to dry under ambient conditions.
  • the appropriate quantity of the initiator is dispensed directly onto the differential scanning calorimetric pan.
  • 25 ⁇ l of the chosen monomer solution is pipetted into the pan. The time taken for the monomer composition to polymerize to the point of a gel is the polymerization time.
  • the initiator and/or the rate modifier can be, but does not have to be, bioactive.
  • the method of the invention can be used to close, cover, or protect tissue and wounds while simultaneously providing a bioactive material to the tissue or wound.
  • the bioactive material is applied onto the tip in an amount that is effective to initiate polymerization and to be effective for the biological activity intended (e.g., in a sufficient amount to be antiseptic).
  • the bioactive material is selected in conjunction with the polymerizable monomer to be dispensed such that the bioactive material functions as an initiator or rate modifier for the monomer.
  • the bioactive material is mixed with the monomer composition.
  • the bioactive material can be released to the tissue to be treated at a constant, or near constant, rate over a period of time while the polymerized composition is in contact with the wound site.
  • the bioactive material can, but need not, be a polymerization initiator or rate modifier.
  • an initiator or rate modifier can also be applied to the tip along with the bioactive material.
  • the bioactive material can be applied to the applicator tip in a solution comprising a low boiling point solvent, especially one comprising methanol.
  • any suitable solvent including water and other aqueous solvents can be used to apply the bioactive material.
  • the bioactive material is solubilized, dissolved, or otherwise dispersed in the adhesive composition as the composition enters and leaves the tip.
  • the bioactive material similarly mixes with the adhesive composition prior to, and during, application of the adhesive.
  • Coapplication of the bioactive material and adhesive composition allows this mixing to occur. Further mixing can occur once the adhesive composition bioactive material has been dispensed at the wound site.
  • Such coapplication e.g., coelution
  • coelution of the bioactive material and the adhesive composition provides an advantage not disclosed in the prior art.
  • Suitable bioactive materials include, but are not limited to, medicaments such as antibiotics, antimicrobials, antiseptics, bacteriocins, bacteriostats, disinfectants, steroids, anesthetics, antifungal agents, anti-inflammatory agents, antibacterial agents, antiviral agents, antitumor agents, growth promoting substances, antioxidants, or mixtures thereof.
  • medicaments such as antibiotics, antimicrobials, antiseptics, bacteriocins, bacteriostats, disinfectants, steroids, anesthetics, antifungal agents, anti-inflammatory agents, antibacterial agents, antiviral agents, antitumor agents, growth promoting substances, antioxidants, or mixtures thereof.
  • Such compounds include, but are not limited to, acetic acid, aluminum acetate, bacitracin, bacitracin zinc, benzalkonium chloride, benzethonium chloride, betadine, calcium chloroplatinate, certrimide, cloramine T, chlorhexidine phosphanilate, chlorhexidine, chlorhexidine sulfate, chloropenidine, chloroplatinatic acid, ciprofloxacin, clindamycin, clioquinol, cysostaphin, gentamicin sulfate, hydrogen peroxide, iodinated polyvinylidone, iodine, iodophor, minocycline, mupirocin, neomycin, neomycin sulfate, nitrofurazone, non-onynol 9, potassium permanganate, penicillin, polymycin, polymycin B, polymyxin, polymyxin B sulfate, polyviny
  • Preferable bioactive materials are USP approved, more preferably USP monographed.
  • an additional polymerization initiator or rate modifier it is possible to formulate the applicator such that the adhesive can be initiated by the tip structural material when it is applied to the desired surface.
  • the applicator tip could be treated with a basic agent, after or preferably before or during its attachment to an applicator body. Treatment with such an agent, such as a caustic agent or alkyl hydroxide, can cause reticulation of the applicator tip material, which in turn results in an applicator tip that is self-initiating when the polymerizable material comes into contact with the applicator tip.
  • additional polymerization initiators or rate modifiers could be omitted, because a desired initiation and polymerization rate could be selected by proper treatment of the applicator tip material.
  • the applicator tip material can be treated with any suitable agent, so long as the objectives of the invention are maintained.
  • suitable agents include, but are not limited to, caustic soda (NaOH), potassium hydroxide, other hydroxides of light metals, ammonium hydroxide, alkyl hydroxides, caustic alcohol
  • the applicator tip can also include various other materials that may or may not act as a polymerization initiator or rate modifier.
  • the applicator tip can include a flavorant, such that it imparts a flavor to the adhesive material when the adhesive material is applied to a surface. Incorporation of a flavorant is particularly preferred, for example, when the cyanoacrylate adhesive material is to be applied to oral surfaces, such as to treat stomatitis or cold sores.
  • a flavorant is to be included, any of the various available and suitable flavorants can be used. Suitable flavorants can be selected, for example, from among fruit oil, vegetable oil, esters, heterocyclic compounds, fruit extract and vegetable extract.
  • the flavoring additive may be selected from among any of the various known flavoring additives, including, but not limited to, 5-fold orange oil (Florida Chemical Co.), anethole (Aldrich), banana distillate (Florida Chemical Co.), benzaldehyde (Aldrich), clove oil (Humco), cold pressed Valencia orange oil (Florida Chemical Co.), cold pressed grapefruit oil (Florida Chemical Co.), cold pressed lemon oil (Florida Chemical Co.), cold pressed lime oil (Florida Chemical Co.), cucumber distillate (Florida Chemical Co.), honey distillate (Florida Chemical Co.), menthol (Aldrich), alkyl salicylates such as methyl salicylate (Lorann Oils or Aldrich), monosodium glutamate, spearmint, wintergreen, cinnamon, citrus, cherry, apple, peppermint, peppermint oil (Humco), peppermint spirit, vanillin (Aldrich), thymol (Aldrich), and
  • the flavorant can also be a sweetener, such as a suitable sugar or sugar substitute.
  • sweeteners include, but are not limited to, saccharin, sorbitol, mannitol, aspartame, sucrose, glucose, fructose, and the like.
  • the flavoring additive is a flavoring agent as defined in 21 C.F.R. ⁇ 172.510, dated June 12, 1989, and ⁇ 172.515, dated April 1, 1996, the entireties of which are incorporated herein by reference.
  • Flavoring additives are also disclosed in U.S. Patent Application No. 09/343,914, filed June 30, 1999, the entire disclosure of which is incorporated herein by reference.
  • the flavoring additive is selected such that it is preferably compatible with the monomer (i.e., does not adversely affect polymerization, bond strength, cure properties, or shelf-life).
  • the flavoring additive is soluble in the monomer composition at room temperature (i.e., 20-25°C) so that it may be readily solubilized in the monomer composition while the monomer composition is in contact with or passing through the applicator tip.
  • the flavoring additive is selected such that it is preferably compatible with the applicator tip and any other components that are to be incorporated into or on the applicator tip.
  • the flavoring additive is used in an amount to provide the desired flavor level to the final polymerized adhesive.
  • the flavorant can be provided in an amount of, for example, from about 0.001-25.0% by weight of the adhesive composition to be applied.
  • the flavoring additive is incorporated in an amount of from about 0.2-10.0%), more preferably 0.5-5.0%, of the adhesive composition.
  • additive amounts outside of these ranges can be readily used depending upon, for example, the desired result to be achieved and the relative flavoring strength of the particular additive.
  • the amount of flavoring additive to be used can be determined by one of ordinary skill in the art based on the present disclosure using known techniques without undue experimentation.
  • the flavorant can be applied in combination with a delivery substrate to facilitate incorporation of the flavorant into or on the applicator tip.
  • suitable delivery substrates include, but are not limited to, waxes, such as carnauba, petroleum and carbowax; gels, such as gelatin, hydroxypropyl methylcellulose, carboxymethylcellulose, and hydroxy-gels; polyethylene glycol; polysorbate; agar; povidone; sodium stearate; starch; powdered sugar; high fructose corn syrup; fructose; glycerin; hydrogenated glucose syrup; sorbitol; mannitol; sucrose; cellulose acetate phthalate; dextrose; polyvinyl alcohol; mixtures thereof; and the like.
  • a preservative into the applicator tip in addition to the flavorant, to help preserve and maintain the flavoring effect of the flavorant.
  • the need for such a preservative can depend, for example, upon the concentration and nature of flavorant, or lack thereof, in the applicator tip.
  • Suitable preservatives generally include the known food preservatives, such as sodium benzoate, salt, citric acid, benzoic acid, sodium nitrite, sodium phosphate, and the like.
  • the flavorant, delivery substrate and/or preservative do not adversely affect the applicator tip.
  • these materials do not adversely affect the aging and/or shelf-life of the applicator tip.
  • the present invention is also directed to a method of applying the adhesive composition utilizing an applicator comprising a tip having a polymerization initiator, a polymerization rate modifier, a bioactive material and/or a flavorant thereon or therein.
  • an applicator comprising a tip having a polymerization initiator, a polymerization rate modifier, a bioactive material and/or a flavorant thereon or therein.
  • any appropriate design for the applicator can be used.
  • Such applicator designs include, but are not limited to, swab applicators, syringes, adhesive guns, pipettes, eyedroppers, vials, and the like with various dispensing nozzles or tips.
  • Suitable applicators may incorporate or be packaged, such as in saleable kits, with one or more containers containing the adhesive composition and/or other components.
  • the applicator tip may be permanently fixed to or detachable from an applicator container holding the polymerizable and/or cross-linkable material.
  • an applicator tip could be attached to the applicator container prior to use and detached from the applicator container subsequent to use in order to prevent premature polymerization or cross-linking of the unapplied material in the applicator container.
  • the applicator tip may be discarded and a new applicator tip may be attached to the applicator container for subsequent use, or the applicator tip may be cleaned and reused.
  • the applicator tip can be a swab attached to a suitable applicator body, such as a plastic, wood, metal or other suitable material handle or holder.
  • Such an applicator can be used, for example, to apply adhesive material from a separate container.
  • the adhesive material can be applied by dipping the swab into the adhesive material, or by otherwise transferring the adhesive material to the swab, and then applying the adhesive material to the desired surface.
  • the applicator including the swab tip can be provided separately, or as part of a saleable kit that includes both the applicator and a quantity of adhesive material, which may be either operably connected to the applicator tip or swab, or located in a separate container.
  • a quantity of adhesive material which may be either operably connected to the applicator tip or swab, or located in a separate container.
  • the applicator tip can include any or all of the various materials described above.
  • the applicator tip in such swab embodiments includes a polymerization initiator or rate modifier that may also be a bioactive material and/or a flavorant.
  • the applicator tip according to the present invention may comprise multiple parts, with at least one part having the initiator, rate modifier, bioactive material and/or flavorant.
  • the component containing the initiator, rate modifier, bioactive material and/or flavorant may be fabricated separately from the other component(s) of the applicator tip and assembled prior to attachment to the applicator body or container.
  • the applicator tip may also be in the form of a nozzle for atomizing liquid polymerizable and/or cross-linkable materials. Conical, flat spray or condensed stream nozzles are suitable.
  • the applicator tip and the applicator container may be an integral or even monolithic unit. The unit may be preformed as a single piece and charged with polymerizable and/or cross-linkable material. After application of material from the applicator container, the unit may be discarded. Additionally, such an integral or monolithic applicator tip/applicator container unit may be fashioned to provide the capability of recharging the unit with new material as a multiple use device.
  • the applicator tip may be composed of any of a variety of materials including polymerized materials such as plastics, foams, rubber, thermosets, films, fibers, or membranes. Where foams are used in the applicator tip, the foam can be either an open-celled form, a closed-cell foam, or a mixture thereof. Any suitable foam material can be used and include, for example, thermoplastic polyurethane foam. In swab tip embodiments, the foam is preferably a soft, absorbent thermoplastic polyurethane foam. In embodiments, the applicator tip may be made from polyurethane, polyesters, polyolefins such as polyethylene, or polyamides.
  • the applicator may be made from polyethylene, such as that sold by Porex Technologies Corp. (Fairburn, GA) under the name LabPor ® .
  • the applicator tip can also be made from fibers, either natural or synthetic, such as cotton, rayons, nylons, and mixtures thereof.
  • the applicator tip may be composed of materials such as metal, glass, paper, ceramics, and the like.
  • the applicator tip material may be porous, absorbent, or adsorbent in nature to enhance and facilitate loading of a material on or in the applicator tip.
  • the applicator tip may be composed of a material having random pores, capillaries, a honeycomb material, a material having a woven pattern, etc. The degree of porosity will depend on the materials being used, and can be determined easily by one of ordinary skill in the art. Porosity is the open volume within the pores of an applicator tip divided by the total volume of the applicator tip.
  • the applicator tip may be porous and have an average pore size of about 1 ⁇ m to about 500 ⁇ m.
  • an applicator tip having an average pore size of about 1-100 ⁇ m such as 10-30 is used with a polymerizable material having a viscosity of about 1-30 cPs, preferably about 2-18 cPs, and more preferably 5-7 cPs at 25°C.
  • An applicator tip having an average pore size of from about 1 ⁇ m to about 100 ⁇ m is preferably used with a polymerizable material having a viscosity of about 10-30 cPs.
  • the average pore size of the applicator tip is generally increased.
  • an applicator tip having an average pore size of about 100-200 ⁇ m such as 140 ⁇ m is preferably used with a polymerizable material having a viscosity of about 30-500 cPs, preferably about 35- 350 cPs, and more preferably about 200-300 cPs at 25°C.
  • an applicator tip has a porosity of less than or equal to 80 percent.
  • the amount of initiator or rate modifier necessary to initiate and/or to modify the rate of polymerization and/or cross-linking increases as the pore size of the applicator tip increases.
  • the applicator tip can have a variety of suitable shapes and sizes. Generally, the dimensional characteristics are limited only by the intended use of the applicator, and practicality considerations. Suitable shapes include, but are not limited to, conical, cylindrical, chisel or polygonal shapes. The length and size of the tip can be varied depending on various application parameters. The tip may be detachable from the applicator body, or may be an integral part of the applicator.
  • the applicator tip according to the present invention, where it connects to the applicator tube may have an elongated tubular portion, out of which the mixed polymerizing and/or cross-linking material is expelled.
  • a portion of the applicator tip which is immediately downstream of the applicator tube is advantageously porous in order to avoid a sharp pressure drop and ensure a constant mixed ratio profile.
  • the structure can preferably trap fragments of any barriers or materials used to separate one or more components within the applicator container so that they will not clog the device or contact the patient.
  • the composition When using a porous applicator tip to apply the adhesive composition, the composition preferably is not expressed directly through the applicator tip in a continuous motion.
  • the adhesive composition is (1) expressed to the end or part way to the end of the applicator tip, (2) the pressure is released to draw the composition back into the applicator, and (3) the composition is then subsequently expressed through the applicator tip in a continuous motion. This is called a suck-back method of applying the adhesive composition of the present invention. When used with a tip that bears an initiator, this method lets the adhesive composition polymerize more slowly than if it had been expressed directly through the tip.
  • the initiator, rate modifier, bioactive material and/or flavorant may be in the form of a solid, such as a powder or a solid film, or in the form of a liquid, such as a viscous or paste-like material.
  • the tip may also include a variety of additives, such as surfactants or emulsifiers.
  • the initiator, rate modifier, bioactive material and/or flavorant is soluble or otherwise dispersible in the polymerizable and/or cross- linkable material, and/or comprises or is accompanied by at least one surfactant which helps it co-elute with the polymerizable and/or cross-linkable material.
  • the surfactant may help solubilize it in the polymerizable and/or cross- linkable material.
  • the initiator, rate modifier, bioactive agent and/or flavorant thus mixes with the adhesive composition as the mixture passes through the tip.
  • the present invention provides a method of wound treatment, including wound closure.
  • the methods of this invention can be used as replacements for, or in addition to, sutures or staples to join together two surfaces by applying the present compositions to opposing wound surfaces that are then held together while polymerization proceeds.
  • the methods of this invention can also be used to coat, protect, or otherwise cover surface, superficial, or otherwise topical wounds including, but not limited to, minor cuts, scrapes, irritations, compromised skin, superficial lacerations, abrasions, burns, sores, and stomatitis.
  • the methods of the invention can also be used on tissues that do not show any signs of tissue damage.
  • the methods can be used to deliver medicaments to a patient through healthy tissue. They can also be used, for example, to locally deliver medicaments to tissues such as tumors or organs.
  • the present invention provides a replacement for sutures or staples and includes a method of joining together in vivo two surfaces, comprising: (a) holding together tissue surfaces of a wound or incision to form an abutted tissue surface; (b) applying to the abutted tissue surface a composition of the present invention; and (c) maintaining the surfaces in contact until the composition polymerizes.
  • a subsequent coating may be applied immediately after application of a previous coating or after a previous coating has been completely polymerized.
  • the monomer composition applied to the abutted tissue surface is allowed to at least partially polymerize prior to subsequent coatings or applications of additional monomer composition.
  • a coating of an adhesive composition of the present invention having a monomer different from the monomer of the first or previous coating may be applied as the second or subsequent coating.
  • Repairing injured tissues comprises, in general, sponging to remove superficial body fluids, holding injured tissue surfaces together in an abutting relationship and subsequent application to the exposed abutted tissue of the present adhesive composition.
  • the composition polymerizes to a thin film of polymer while in contact with the abutted tissue surface. Tissues which are not bleeding or otherwise covered by body fluids need not be sponged first. More than one coating or application of monomer composition may be applied to the abutted tissue surface. Desired bonding of tissues or hemostasis proceeds well in the presence of blood and other body fluids. The bonds formed are of adequate flexibility and strength to withstand normal movement of tissue. In addition, bond strength is maintained as natural wound healing proceeds.
  • the present invention is directed to a method of treating a superficial or topical wound, such as a skin wound or a wound on a mucous membrane which comprises (a) applying a composition of the present invention to the superficial wound; (b) allowing the composition to polymerize; and (c) optionally, applying the composition at least once more to the coated superficial wound.
  • a superficial or topical wound such as a skin wound or a wound on a mucous membrane
  • Suitable film thickness for wound closure in the cases where the adhesive is replacing sutures range from 0.1 mm to 2.0 mm or 3.0 mm or higher, preferably from 0.2 mm to 1.5 mm, and more preferably from 0.4 mm to 0.8 mm.
  • Suitable film thickness for other applications range from l ⁇ m to lOOO ⁇ m.
  • the biocompatible film formed for replacement of sutures may have an in vivo film strength of at least 70 mm Hg of vacuum pressure required to induce wound failure, generally from 70 mm Hg to 400 mm Hg of vacuum pressure required to induce wound failure, preferably from 90 mm Hg to 400 mm Hg of vacuum pressure required to induce wound failure, and more preferably from 100 mm Hg to 400 mm Hg of pressure required to induce wound failure.
  • the biocompatable film formed for other applications may have an in vivo film strength of 5-400 mm Hg of vacuum pressure required to induce wound failure, more preferably
  • the present invention is not limited to such embodiments.
  • the material or materials can be introduced into or onto the applicator tip during the process of manufacturing the applicator tip.
  • the initiator and/or other material is incorporated directly into or onto the applicator tip during manufacture of the tip.
  • the initiator and/or other material can be incorporated into the applicator at any suitable stage during the manufacturing process.
  • the material can be incorporated into the applicator tip prior to, concurrent with or subsequent to molding of the applicator tip.
  • the material can be mixed with the pellets used to form the applicator tip, such that the mixture is molded to form the applicator tip.
  • the material is a liquid or can be dissolved into a suitable carrier liquid, the material can be absorbed into or adsorbed onto the pellets prior to molding, or can be applied as a release agent to the mold.
  • An advantage of using foams for the applicator tip is that the materials described herein can be incorporated into the foam during or after the foam formation.
  • the materials can be incorporated into the foam, for example, by introducing them into the foam during the blowing process, by adding them as a release agent to remove the foam from a mold, and the like.
  • These processes provide alternative means to incorporate the initiator or other material into or onto the applicator tip in a controlled manner, without need for a subsequent step of applying the material to the pre-formed applicator tip.
  • the present invention involves a polymerizable adhesive composition, such as a monomer composition comprising:
  • the composition preferably comprises a monomeric (or prepolymeric) adhesive.
  • the monomer is a 1,1 -disubstituted ethylene monomer, for example, an ⁇ -cyanoacrylate.
  • the monomer composition comprises a bioactive material. Preferred compositions of the present invention and polymers formed therefrom are useful as tissue adhesives, sealants for preventing bleeding or for covering open wounds, and in other biomedical applications.
  • Monomers that may be used in this invention are readily polymerizable, e.g. anionically polymerizable or free radical polymerizable, or polymerizable by zwitterions or ion pairs to form polymers.
  • Such monomers include those that form polymers that may, but do not need to, biodegrade.
  • Such monomers are disclosed in, for example, U.S. Patent No. 5,328,687, which is hereby incorporated in its entirety by reference herein.
  • Useful 1,1 -disubstituted ethylene monomers include, but are not limited to, monomers of the formula:
  • R 2 is hydrogen and R 3 is a hydrocarbyl or substituted hydrocarbyl group; a group having the formula -R 4 -O-R 5 -O-R 6 or the formula -R 5 -O-R 6 , wherein R 4 is a 1,2- alkylene group having 2-4 carbon atoms, R 5 is an alkylene group having 2-4 carbon atoms, and R 6 is an alkyl
  • R 7 is -(CH 2 ) n -, -CH-, or -C(CH 3 ) 2 -, wherein n is 1-10, preferably 1-5 carbon atoms, and R 8 is an organic radical.
  • suitable hydrocarbyl and substituted hydrocarbyl groups include straight chain or branched chain alkyl groups having 1-16 carbon atoms; straight chain or branched chain C r C 16 alkyl groups substituted with an acyloxy group, a haloalkyl group, an alkoxy group, a halogen atom, a cyano group, or a haloalkyl group; straight chain or branched chain alkenyl groups having 2 to 16 carbon atoms; straight chain or branched chain alkynyl groups having 2 to 12 carbon atoms; cycloalkyl groups; aralkyl groups; alkylaryl groups; and aryl groups.
  • the organic moiety R 8 may be substituted or unsubstituted and may be straight chain, branched or cyclic, saturated, unsaturated or aromatic.
  • organic moieties include -Cg alkyl moieties, C 2 -C 8 alkenyl moieties, C 2 -C 8 alkynyl moieties, C 3 -C 12 cycloaliphatic moieties, aryl moieties such as phenyl and substituted phenyl and aralkyl moieties such as benzyl, methylbenzyl and phenylethyl.
  • organic moieties include substituted hydrocarbon moieties, such as halo (e.g., chloro-, fluoro- and bromo-substituted hydrocarbons) and oxy- (e.g., alkoxy substituted hydrocarbons) substituted hydrocarbon moieties.
  • Preferred organic radicals are alkyl, alkenyl and alkynyl moieties having from 1 to about 8 carbon atoms, and halo-substituted derivatives thereof. Particularly preferred are alkyl moieties of 4 to 6 carbon atoms.
  • R 3 is preferably an alkyl group having 1-10 carbon atoms or a group having the formula -AOR 9 , wherein A is a divalent straight or branched chain alkylene or oxyalkylene moiety having 2-8 carbon atoms, and R 9 is a straight or branched alkyl moiety having 1-8 carbon atoms.
  • Examples of groups represented by the formula -AOR 9 include l-methoxy-2- propyl, 2-butoxy ethyl, isopropoxy ethyl, 2-methoxy ethyl, and 2-ethoxy ethyl.
  • Preferred ⁇ -cyanoacrylate monomers used in this invention include 2-octyl cyanoacrylate, dodecyl cyanoacrylate, 2-ethylhexyl cyanoacrylate, butyl cyanoacrylate, methyl cyanoacrylate, 3-methoxybutyl cyanoacrylate, 2-butoxy ethyl cyanoacrylate, 2-isopropoxyethyl cyanoacrylate, or l-methoxy-2-propyl cyanoacrylate.
  • the ⁇ -cyanoacrylates of formula (II) can be prepared according to methods known in the art.
  • the ⁇ -cyanoacrylates can be prepared by reacting an alkyl cyanoacetate with formaldehyde in a non-aqueous organic solvent and in the presence of a basic catalyst, followed by pyrolysis of the anhydrous intermediate polymer in the presence of a polymerization inhibitor.
  • the ⁇ -cyanoacrylate monomers prepared with low moisture content and essentially free of impurities are preferred for biomedical use.
  • the ⁇ -cyanoacrylates of formula (II) wherein R 3 is a group having the formula R 4 -O-R 5 -O-R 6 or the formula -R 5 -O-R 6 can be prepared according to the method disclosed in U.S. Patent No. 4,364,876 to Kimura et al., which is hereby incorporated by reference. In the Kimura et al.
  • the ⁇ -cyanoacrylates are prepared by producing a cyanoacetate by esterifying cyanoacetic acid with an alcohol or by transesterifying an alkyl cyanoacetate and an alcohol; condensing the cyanoacetate and formaldehyde or para-formaldehyde in the presence of a catalyst at a molar ratio of 0.5-1.5:1, preferably 0.8-1.2:1, to obtain a condensate; depolymerizing the condensation reaction mixture either directly or after removal of the condensation catalyst to yield crude cyanoacrylate; and distilling the crude cyanoacrylate to form a high purity cyanoacrylate.
  • Patent No. 3,995,641 to Kronenthal et al. which is hereby incorporated by reference.
  • such ⁇ -cyanoacrylate monomers are prepared by reacting an alkyl ester of an ⁇ -cyanoacrylic acid with a cyclic 1,3-diene to form a Diels- Alder adduct which is then subjected to alkaline hydrolysis followed by acidification to form the corresponding ⁇ -cyanoacrylic acid adduct.
  • the ⁇ - cyanoacrylic acid adduct is preferably esterified by an alkyl bromoacetate to yield the corresponding carbalkoxymethyl ⁇ -cyanoacrylate adduct.
  • the ⁇ - cyanoacrylic acid adduct may be converted to the ⁇ -cyanoacrylyl haiide adduct by reaction with thionyl chloride.
  • the ⁇ -cyanoacrylyl haiide adduct is then reacted with an alkyl hydroxyacetate or a methyl substituted alkyl hydroxyacetate to yield the corresponding carbalkoxymethyl ⁇ -cyanoacrylate adduct or carbalkoxy alkyl ⁇ - cyanoacrylate adduct, respectively.
  • the cyclic 1,3-diene blocking group is finally removed and the carbalkoxy methyl ⁇ -cyanoacrylate adduct or the carbalkoxy alkyl ⁇ -cyanoacrylate adduct is converted into the corresponding carbalkoxy alkyl ⁇ - cyanoacrylate by heating the adduct in the presence of a slight deficit of maleic anhydride.
  • Examples of monomers of formula (II) include cyanopentadienoates and ⁇ - cyanoacrylates of the formula:
  • component B) is at least one plasticizing agent that imparts flexibility to the polymerized monomer formed on the wound, incision, or abrasion.
  • the plasticizing agent preferably contains little or no moisture and should not significantly affect the polymerization of the monomer.
  • plasticizers examples include acetyl tributyl citrate, dimethyl sebacate, triethyl phosphate, tri(2-ethylhexyl)phosphate, tri(p-cresyl) phosphate, glyceryl triacetate, glyceryl tributyrate, diethyl sebacate, dioctyl adipate, isopropyl myristate, butyl stearate, lauric acid, trioctyl trimellitate, dioctyl glutarate and mixtures thereof.
  • Preferred plasticizers are tributyl citrate and acetyl tributyl citrate.
  • suitable plasticizers include polymeric plasticizers, such as polyethylene glycol (PEG) esters and capped PEG esters or ethers, polyester glutarates and polyester adipates.
  • PEG polyethylene glycol
  • component C) is at least one stabilizing agent that inhibits polymerization.
  • stabilizing agents may also include mixtures of anionic stabilizing agents and radical stabilizing agents.
  • anionic stabilizing agents include, but are not limited to, sultones (e.g., ⁇ -chloro- ⁇ -hydroxy-o-toluenesulfonic acid- ⁇ -sultone), sulfur dioxide, sulfuric acid, sulfonic acid, lactone, boron trifluoride, organic acids, such as acetic acid or phosphoric acid, alkyl sulfate, alkyl sulfite, 3-sulfolene, alkylsulfone, alkyl sulfoxide, mercaptan, and alkyl sulfide and mixtures thereof.
  • Preferable anionic stabilizing agents are acidic stabilizing agents of organic acids such as acetic acid or phosphoric acid.
  • the amount of sulfur dioxide stabilizer is less than 100 ppm, preferably 5-75 ppm, and more preferably from about 20-50 ppm.
  • the amount of sultone and/or trifluoracetic acid is about 500-3000 ppm.
  • suitable radical stabilizing agents include hydroquinone, hydroquinone monomethyl ether, catechol, pyrogallol, benzoquinone, 2- hydroxybenzoquinone, p-methoxy phenol, t-butyl catechol, butylated hydroxy anisole (BHA), butylated hydroxy toluene, and t-butyl hydroquinone.
  • the amount of BHA is about 1,000-5,000 ppm.
  • Suitable acidic stabilizing agents include those having aqueous pKa ionization constants ranging from -12 to 7, about -5 to about 7, preferably from about -3.5 to about 6.
  • suitable acidic stabilizing agents include: hydrogen sulfide (pKa 7.0), carbonic acid (pKa 6.4), triacetylmethane (pKa 5.9), acetic acid (pKa 4.8), benzoic acid (pKa 4.2), 2,4-dinitrophenol (pKa 4.0), formic acid (pKa 3.7), nitrous acid (pKa 3.3), hydrofluoric acid (pKa 3.2), chloroacetic acid (pKa 2.9), phosphoric acid (pKa 2.2), dichloroacetic acid (pKa 1.3), trichloroacetic acid (pKa 0.7), 2,4,6- trinitrophenol (picric acid) (pKa 0.3), trifluoroacetic acid (pKa 0.2), sulfuric acid (pK
  • the amount of trifluoroacetic acid is about 500-1,500 ppm.
  • Combinations of the above stabilizers such as sulfur dioxide and sulfuric acid, boron trifluoride and sulfuric acid, sulfur dioxide and chloroacetic acid, boron trifluoride and chloroacetic acid, sulfur dioxide and trifluoroacetic acid, and boron trifluoride and triflouroacetic acid can be used.
  • plasticizing agents in amounts ranging from about 0.5 wt.% to about 16 wt.%, preferably from about 3 wt.% to about 9 wt.%, and more preferably from about 5 wt.% to about 7 wt.% provides increased film strength (e.g., toughness) of the polymerized monomer over polymerized monomers having amounts of plasticizing agents and acidic stabilizing agents outside of the above ranges.
  • the concentration of the acidic stabilizing agents utilized may vary depending on the strength of the acid. For example, when using acetic acid, a concentration of 80-200 ppm (wt/wt), preferably 90-180 ppm (wt/wt), and more preferably 100-150 ppm (wt/wt) may be utilized. When using a stronger acid such as phosphoric acid, a concentration range of 20-80 ppm (wt/wt), preferably, 30-70 ppm (wt/wt) and more preferably 40-60 ppm (wt/wt) may be utilized. In embodiments, the amount of trifluoroacetic acid is about 100 to 3000 ppm, preferably 500-1500 ppm. In other embodiments, the amount of phosphoric acid is about 10-200 ppm, preferably about 50-150 ppm, and more preferably about 75-125 ppm.
  • compositions of the present invention may also include at least one biocompatible agent effective to reduce active formaldehyde concentration levels produced during in vivo biodegradation of the polymer (also referred to herein as "formaldehyde concentration reducing agents").
  • this component is a formaldehyde scavenger compound.
  • formaldehyde scavenger compounds useful in this invention include sulfites; bisulfites; mixtures of sulfites and bisulfites; ammonium sulfite salts; amines; amides; imides; nitriles; carbamates; alcohols; mercaptans; proteins; mixtures of amines, amides, and proteins; active methylene compounds such as cyclic ketones and compounds having a b-dicarbonyl group; and heterocyclic ring compounds free of a carbonyl group and containing an
  • NH group with the ring made up of nitrogen or carbon atoms, the ring being unsaturated or, when fused to a phenyl group, being unsaturated or saturated, and the NH group being bonded to a carbon or a nitrogen atom, which atom is directly bonded by a double bond to another carbon or nitrogen atom.
  • Bisulfites and sulfites useful as the formaldehyde scavenger compound in this invention include alkali metal salts such as lithium, sodium and potassium salts, and ammonium salts, for example, sodium bisulfite, potassium bisulfite, lithium bisulfite, ammonium bisulfite, sodium sulfite, potassium sulfite, lithium sulfite, ammonium sulfite, and the like.
  • amines useful in this invention include the aliphatic and aromatic amines such as, for example, aniline, benzidine, aminopyrimidine, toluene-diamine, triethylenediamine, diphenylamine, diaminodiphenylamine, hydrazines and hydrazide.
  • Suitable proteins include collagen, gelatin, casein, soybean protein, vegetable protein, keratin and glue.
  • the preferred protein for use in this invention is casein.
  • Suitable amides for use in this invention include urea, cyanamide, acrylamide, benzamide, and acetamide.
  • Urea is a preferred amide.
  • Suitable alcohols include phenols, 1,4-butanediol, d-sorbitol, and polyvinyl alcohol.
  • Suitable compounds having a b-dicarbonyl group include malonic acid, acetylacetone, ethylacetone, acetate, malonamide, diethylmalonate or another malonic ester.
  • Preferred cyclic ketones for use in this invention include cyclohexanone or cyclopentanone.
  • heterocyclic compounds for use as the formaldehyde scavenger in this invention are disclosed, for example, in U.S. Patent No. 4,127,382 (Perry) which is hereby incorporated by reference herein.
  • Such heterocyclic compounds include, for example, benzimidazole, 5 -methyl benzimidazole, 2- methylbenzimidazole, indole, pyrrole, 1,2,4-triazole, indoline, benzotriazole, indoline, and the like.
  • a preferred formaldehyde scavenger for use in this invention is sodium bisulfite.
  • the formaldehyde concentration reducing agent e.g., formaldehyde scavenger compound
  • the "effective amount” is that amount sufficient to reduce the amount of formaldehyde generated during subsequent in vivo biodegradation of the polymerized cyanoacrylate. This amount will depend on the type of active formaldehyde concentration reducing agent, and can be readily determined without undue experimentation by those skilled in the art.
  • the formaldehyde concentration reducing agent may be used in this invention in either free form or in microencapsulated form.
  • Other compositions are exemplified by U.S. Patent Application Serial No. 08/714,288, incorporated by reference herein in its entirety.
  • the formaldehyde concentration reducing agent is released from the microcapsule continuously over a period of time during the in vivo biodegradation of the cyanoacrylate polymer.
  • the microencapsulated form of the formaldehyde concentration reducing agent is preferred because this embodiment prevents or substantially reduces polymerization of the cyanoacrylate monomer by the formaldehyde concentration reducing agent, which increases shelf-life and facilitates handling of the monomer composition during use.
  • Microencapsulation of the formaldehyde scavenger can be achieved by many known microencapsulation techniques.
  • microencapsulation can be carried out by dissolving a coating polymer in a volatile solvent, e.g., methylene chloride, to a polymer concentration of about 6% by weight; adding a formaldehyde scavenger compound in particulate form to the coating polymer/solvent solution under agitation to yield a scavenger concentration of 18% by weight; slowly adding a surfactant-containing mineral oil solution to the polymer solution under rapid agitation; allowing the volatile solvent to evaporate under agitation; removing the agitator; separating the solids from the mineral oil; and washing and drying the microparticles.
  • the size of the microparticles will range from about 0.001 to about 1000 microns.
  • the coating polymer for microencapsulating the formaldehyde concentration reducing agent should be polymers which undergo in vivo bioerosion, preferably at rates similar to or greater than the cyanoacrylate polymer formed by the monomer, and should have low inherent moisture content. Such bioerosion can occur as a result of the physical or chemical breakdown of the encapsulating material, for example, by the encapsulating material passing from solid to solute in the presence of body fluids, or by biodegradation of the encapsulating material by agents present in the body.
  • polyesters such as polygly colic acid, poly lactic acid, poly-l,4-dioxa-2-one, polyoxaltes, polycarbonates, copolymers of polygly colic acid and poly lactic acid, polycaprolactone, poly-b-hydroxybutyrate, copolymers of epsilon-caprolactone and delta- valerolactone, copolymers of epsilon- caprolactone and DL-dilactide, and polyester hydrogels; polyvinylpyrrolidone; polyamides; gelatin; albumin; proteins; collagen; poly(orthoesters); poly(anhydrides); poly(alkyl-2-cyanoacrylates); poly(dihydropyrans); poly(acetals); poly(phosphazenes); poly(urethanes); poly(dioxinones); cellulose; and starches.
  • polyesters such as polygly colic acid, poly lactic acid, poly-l,4-diox
  • component D) is a thickening agent.
  • suitable thickeners include, for example, poly cyanoacrylates, poly lactic acid, poly-l,4-dioxa-2-one, polyoxalates, polyglycolic acid, lactic-glycolic acid copolymers, polycaprolactone, lactic acid-caprolactone copolymers, poly-3-hydroxybutyric acid, polyorthoesters, polyalkyl acrylates, copolymers of alkylacrylate and vinyl acetate, polyalkyl methacrylates, and copolymers of alkyl methacrylates and butadiene.
  • alkyl methacrylates and acrylates are poly(2-ethylhexyl methacrylate) and poly(2- ethylhexyl acrylate), also poly(butylmethacrylate) and poly(butylacrylate), also copolymers of various acrylate and methacrylate monomers, such as poly(butylmethacrylate-co-methylacrylate).
  • difunctional monomeric cross-linking agents may be added to the monomer compositions of this invention.
  • Such crosslinking agents are known.
  • suitable crosslinking agents include alkyl bis(2-cyanoacrylates), triallyl isocyanurates, alkylene diacrylates, alkylene dimethacrylates, trimethylol propane triacrylate, and alkyl bis(2-cyanoacrylates).
  • a catalytic amount of an amine activated free radical initiator or rate modifier may be added to initiate polymerization or to modify the rate of polymerization of the cyanoacrylate monomer/crosslinking agent blend.
  • compositions of this invention may further contain fibrous reinforcement and colorants, i.e., dyes and pigments.
  • fibrous reinforcement include PGA microfibrils, collagen microfibrils, cellulosic microfibrils, and olefinic microfibrils.
  • suitable colorants include l-hydroxy-4-[4-methylphenyl- amino]-9,10 anthracenedione (D+C violet No. 2); disodium salt of 6-hydroxy-5-[(4- sulfophenyl)axo]-2-naphthalene-sulfonic acid (FD+C Yellow No.
  • compositions that are contemplated by the present invention are exemplified by U.S. Patents Nos. 5,624,669; 5,582,834; 5,575,997; 5,514,371; 5,514,372; and 5,259,835; the disclosures of all of which are hereby incorporated in their entirety by reference.
  • Compositions, including the polymerization initiators, rate modifiers, bioactive materials and/or flavorant, employed in the invention are preferably sterilizable such as by dry heat (e.g. above 100°C), electron beam, gamma irradiation, ethylene oxide or hydrogen peroxide vapor, and other methods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials For Medical Uses (AREA)
  • Coating Apparatus (AREA)

Abstract

L'invention concerne un embout d'applicateur pour un applicateur permettant l'application d'une composition adhésive polymérisable monomère pouvant renfermer un matériel bioactif, une essence, un dispositif d'amorçage de polymérisation et/ou un modificateur de vitesse de polymérisation.
PCT/US2000/041648 1999-10-29 2000-10-27 Embout d'applicateur d'adhesif avec un dispositif d'amorçage de la polymerisation, modificateur de vitesse de polymerisation et/ou materiel bioactif WO2001032319A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36380/01A AU3638001A (en) 1999-10-29 2000-10-27 Adhesive applicator tip with a polymerization initiator, polymerization rate modifier, and/or bioactive material

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43017799A 1999-10-29 1999-10-29
US09/430,177 1999-10-29

Publications (3)

Publication Number Publication Date
WO2001032319A2 WO2001032319A2 (fr) 2001-05-10
WO2001032319A3 WO2001032319A3 (fr) 2001-12-06
WO2001032319A9 true WO2001032319A9 (fr) 2002-08-08

Family

ID=23706381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/041648 WO2001032319A2 (fr) 1999-10-29 2000-10-27 Embout d'applicateur d'adhesif avec un dispositif d'amorçage de la polymerisation, modificateur de vitesse de polymerisation et/ou materiel bioactif

Country Status (2)

Country Link
AU (1) AU3638001A (fr)
WO (1) WO2001032319A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620846B1 (en) * 2000-08-02 2003-09-16 Closure Medical Corporation Absorbable adhesive compositions
DE102007046600A1 (de) * 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
CN108904870A (zh) * 2018-08-01 2018-11-30 浙江派菲特新材料科技有限公司 一种具有促进愈合以及修复功能的医用胶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028848A1 (fr) * 1997-11-03 2000-08-23 MedLogic Global Corporation Compositions de prepolymeres contenant un agent antimicrobien .
WO1999023150A1 (fr) * 1997-11-03 1999-05-14 Medlogic Global Corporation Compositions de polymere de cyanoacrylate contenant un agent antimicrobien
BR9910063A (pt) * 1998-04-30 2000-12-26 Closure Medical Corp Conjunto para fornecer um medicamento a um paciente, e, manufatura de uma embalagem
US6595940B1 (en) * 1998-12-23 2003-07-22 Closure Medical Corporation Applicator for dispensable liquids

Also Published As

Publication number Publication date
AU3638001A (en) 2001-05-14
WO2001032319A3 (fr) 2001-12-06
WO2001032319A2 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
US20050196431A1 (en) Adhesive applicator tip with a polymerization initiator, polymerization rate modifier, and/or bioactive material
AU741078B2 (en) Adhesive applicator with polymerization agents and/or bioactive material
US6455064B1 (en) Method of applying an adhesive composition over a bioactive polymerization initiator or accelerator
US6595940B1 (en) Applicator for dispensable liquids
EP0886507B1 (fr) Compositions monomeres efficaces en tant que dispositifs de fermeture de lesion
US6283933B1 (en) Applicator for dispensable liquids
EP1007110B1 (fr) Procedes relatifs a l'application de compositions monomeres efficaces pour la fermeture des plaies
EP0965623B1 (fr) Compositions adhésives de monomères stabilisés
US20040137067A1 (en) Adhesive applicator tip with a polymerization initiator, polymerization rate modifier, and/or bioactive material
AU759076B2 (en) Use of an adhesive composition over a bioactive polymerization initiator or accelerator
WO2001032319A9 (fr) Embout d'applicateur d'adhesif avec un dispositif d'amorçage de la polymerisation, modificateur de vitesse de polymerisation et/ou materiel bioactif
JP2007061658A (ja) 創傷閉鎖手段として有効な単量体組成物
MXPA00010459A (en) Adhesive applicator with polymerization agents and/or bioactive material
MXPA00010460A (en) Use of an adhesive composition over a bioactive polymerization initiator or accelerator
MXPA00002116A (en) Methods of applying monomeric compositions effective as wound closure devices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)